BDWM
TEVA icon

Brewin Dolphin Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-390
Closed -$4K – 383
2022
Q1 		$4K Buy
+390
New +$3.25K ﹤0.01% 334

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brewin Dolphin Wealth Management's TEVA Position: Q2 2022 in Review

Brewin Dolphin Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2022, closing a stake of 390 shares — an estimated $4K sold.

Brewin Dolphin Wealth Management first reported a position in TEVA in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2022.

  • Brewin Dolphin Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Brewin Dolphin Wealth Management sold 390 Teva Pharmaceuticals shares in Q2 2022, an estimated $4K.
  • Brewin Dolphin Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Brewin Dolphin Wealth Management's Teva Pharmaceuticals position peaked at $4K in Q1 2022.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.